Allergy Therapeutics - Asset Resilience Ratio
Allergy Therapeutics (AGY) has an Asset Resilience Ratio of 0.31% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Allergy Therapeutics's Asset Resilience Ratio has changed over time. Check Allergy Therapeutics strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Allergy Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Allergy Therapeutics worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX200.00K | 0.31% |
| Total Liquid Assets | GBX200.00K | 0.31% |
Asset Resilience Insights
- Limited Liquidity: Allergy Therapeutics maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Allergy Therapeutics Industry Peers by Asset Resilience Ratio
Compare Allergy Therapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Alkermes plc
F:8AK |
Drug Manufacturers - Specialty & Generic | 3.76% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
Annual Asset Resilience Ratio for Allergy Therapeutics (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Allergy Therapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.31% | GBX200.00K ≈ $24.33 |
GBX64.83 Million ≈ $7.89K |
-0.40pp |
| 2017-06-30 | 0.71% | GBX404.00K ≈ $49.16 |
GBX57.18 Million ≈ $6.96K |
+18.93pp |
| 2016-06-30 | -18.23% | GBX-10.33 Million ≈ $-1.26K |
GBX56.68 Million ≈ $6.90K |
-19.77pp |
| 2015-06-30 | 1.54% | GBX783.00K ≈ $95.27 |
GBX50.70 Million ≈ $6.17K |
+0.33pp |
| 2014-06-30 | 1.21% | GBX345.00K ≈ $41.98 |
GBX28.40 Million ≈ $3.46K |
+1.21pp |
| 2013-06-30 | 0.01% | GBX2.00K ≈ $0.24 |
GBX28.96 Million ≈ $3.52K |
-1.73pp |
| 2012-06-30 | 1.74% | GBX483.00K ≈ $58.77 |
GBX27.75 Million ≈ $3.38K |
+1.73pp |
| 2008-06-30 | 0.01% | GBX3.00K ≈ $0.37 |
GBX23.18 Million ≈ $2.82K |
-0.25pp |
| 2007-06-30 | 0.26% | GBX63.00K ≈ $7.67 |
GBX23.99 Million ≈ $2.92K |
-- |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more